Related Experiment Video
Updated: Apr 2, 2026
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
Pilot study of a myostatin antagonist in dogs with cardiac cachexia
Lisa M Freeman1, John E Rush1, Suzanne M Cunningham1
1Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA, USA.
Objectives:
Cardiac cachexia, a loss of lean body mass caused by heart disease, often accompanies congestive heart failure (CHF). Blocking myostatin, which is a protein that inhibits muscle growth, appears to greatly enhance muscle size and strength in rodent models and human clinical trials. The objective of this study was to evaluate a dog-specific myostatin antagonist (CAP-031) in a pilot study to test its safety and efficacy in dogs with CHF and cardiac cachexia.
Animals:
Dogs with CHF and cardiac cachexia.
Methods:
Eligible dogs received four weekly subcutaneous injections of CAP-031. Endpoints were body weight, body condition score (BCS, on a 1-9 scale), muscle condition score (MCS, on a five-point scale, where 0 = no muscle loss and 4 = severe muscle loss), appetite, and a quality of life (QOL) score.
Results:
Seven dogs with CHF and moderate-to-severe cachexia were enrolled in the study. For the six dogs that completed the study, the median age was 8.8 years (range 6.4-10.6). At baseline, the median body weight was 27.0 kg (range 17.3-62.0), the median BCS was 4 (2-5), and median MCS was 3 (3-4). There were no significant changes in body weight, BCS, appetite, or QOL score. The change in MCS (from a median of 3 at baseline to a median of 2.5 at week 4) was not statistically significant (p = 0.06).
Conclusions:
The myostatin antagonist appeared to be well tolerated in most dogs. Earlier identification of cachexia is important, and randomized, controlled trials of myostatin antagonists or other drugs to treat cardiac cachexia are needed.
Insights
This pilot study found that a myostatin antagonist (CAP-031) was well-tolerated in dogs with heart failure and cardiac cachexia, though it did not significantly improve muscle mass or other key indicators. Further research is needed to confirm efficacy.
Area of Science:
- Veterinary Cardiology
- Muscle Physiology
- Pharmacology
Background:
- Cardiac cachexia, a common complication of congestive heart failure (CHF), leads to significant lean body mass loss.
- Myostatin, a protein inhibiting muscle growth, is a potential therapeutic target for muscle wasting conditions.
- Previous studies in rodents and humans suggest myostatin inhibition can enhance muscle mass and strength.
Purpose of the Study:
- To evaluate the safety and efficacy of a novel dog-specific myostatin antagonist, CAP-031.
- To assess the impact of CAP-031 on body weight, body condition score, muscle condition score, appetite, and quality of life in dogs with CHF and cardiac cachexia.
Main Methods:
- A pilot study involving seven dogs diagnosed with congestive heart failure and moderate-to-severe cardiac cachexia.
- Dogs received four weekly subcutaneous injections of CAP-031.
- Key endpoints included body weight, body condition score (BCS), muscle condition score (MCS), appetite, and quality of life (QOL).
Main Results:
- Six dogs completed the study; the myostatin antagonist was generally well-tolerated.
- No statistically significant changes were observed in body weight, BCS, appetite, or QOL scores.
- A non-significant trend towards decreased muscle condition score was noted (median MCS changed from 3 to 2.5, p=0.06).
Conclusions:
- The myostatin antagonist CAP-031 demonstrated good tolerability in dogs with CHF and cardiac cachexia.
- Early identification and intervention for cardiac cachexia are crucial.
- Larger, randomized controlled trials are necessary to determine the therapeutic potential of myostatin antagonists for cardiac cachexia.
